Failed Paxil drug tests in children concealed – Guardian UK
Thu, 5 Feb 2004
The Guardian (UK) reports (below) that BBC Panorama had obtained secret 1998 documents from SmithKline Beecham (now GlaxoSmithKline, GSK) showing that the company deliberately concealed the failure of Seroxat / Paxil to demonstrate a benefit for children in two clinical trials in children.
The Guardian reports that the internal documents state that the company’s goal was: “to effectively manage the dissemination of these data in order to minimise any potential negative commercial impact….It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine [Seroxat / Paxil].”
According to The Guardian, the document states, “positive data” from the first and bigger study, protocol 329, would be published in abstract form at a psychiatric meeting the following month and that a full manuscript of the trial “will be progressed”.
Despite the drug’s failure to show a greater effect than a sugar pill, the 2001 published report in the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), by leading US psychiatric researchers claimed: “Paroxetine is generally well tolerated and effective for major depression in adolescents.”
The Guardian reports that Dr. Alastair Benbow, GSK’s head of European clinical psychiatry, acknowledged that the document “is inconsistent with the facts”.
When did the FDA learn about the misrepresentation of test results? Why is the agency failing to prosecute?
FDA officials selected one of the authors of the 2001 JAACAP article who claimed Paxil was safe and effective for FDA’s psychopharmacology advisory committee. Since that committee is charged with reviewing the data of this– among other Paxil children’s trials–this presents an obvious conflict of interest.
Company ‘held back’ data on drug for children
Antidepressant had no effect, leak reveals
Sarah Boseley, health editor
Tuesday February 3, 2004
The British manufacturers of an antidepressant drug that was last year banned from use in children knew as long ago as 1998 that it did not work and deliberately avoided publishing the full data because of the risk to their lucrative adult market, according to a leaked internal document.
A position paper dated October 1998 shows that managers at SmithKline Beecham – now GlaxoSmithKline – were concerned at the commercial implications of two clinical trials in which their drug Seroxat was given to children and adolescents with major depression.
The results of both trials, known as protocols 329 and 377, showed that the drug was no better than a placebo – an inert pill – in alleviating the children’s depression. An internal unit at the drug company called the Central Medical Affairs team prepared a strategy.
The target, says the document – leaked to the BBC’s Panorama team, which has made two programmes on Seroxat – was “to effectively manage the dissemination of these data in order to minimise any potential negative commercial impact”. About 500,000 adults were at the time taking the drug in the UK. Seroxat was licensed for their use, but not for use in children. Even so, some 8,000 to 10,000 children were also on it because doctors can prescribe an unlicensed drug on their own responsibility.
The paper says that following consultations within the company, SmithKline Beecham would not submit any data to the regulators to get a statement on the efficacy or the safety of the drug. It says: “It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine [Seroxat].” It adds, however, that “positive data” from the first and bigger study, protocol 329, would be published in abstract form at a psychiatric meeting the following month and that a full manuscript of the trial “will be progressed”.
It was eventually published in July 2001 with the conclusion: “Paroxetine is generally well tolerated and effective for major depression in adolescents.”
It was only last spring, after Glaxo submitted the full data from protocols 329 and 377, together with a third study of depressed children on Seroxat and data from trials of the drug in children with obsessive compulsive disorder and social anxiety disorder, that the UK regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), realised that not only was Seroxat ineffective in children but that a bigger proportion of those taking it in the trials thought about killing themselves than among those on placebo. The drug was then banned.
Yesterday Alastair Benbow, GSK’s head of European clinical psychiatry, said the document “draws inappropriate conclusions and it is inconsistent with the facts”.
He insisted that there was no sign of a suicide problem until all the trials were put together.
Richard Brook, the chief executive of Mind, the UK organisation for mental health and a member of the Seroxat review panel convened by the MHRA, said he was appalled by the revelations in the leaked document. To allow the drug to be given to children when there were known side-effects and it could not be proven to work was “morally and ethically bankrupt”, he said.
FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior general interest in receiving similar information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml If you wish to use copyrighted material for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.